Literature DB >> 12682488

Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs.

Wolfgang G Voelckel1, Claus Raedler, Volker Wenzel, Karl H Lindner, Anette C Krismer, Christian A Schmittinger, Holger Herff, Klaus Rheinberger, Alfred Königsrainer.   

Abstract

OBJECTIVE: Epinephrine is widely used for treatment of life-threatening hypotension, although new vasopressor drugs may merit evaluation. The purpose of this study was to determine the effects of vasopressin vs. epinephrine vs. saline placebo on hemodynamic variables, regional blood flow, and short-term survival in an animal model of uncontrolled hemorrhagic shock and delayed fluid resuscitation.
DESIGN: Prospective, randomized, laboratory investigation that used a porcine model for measurement of hemodynamic variables and regional abdominal organ blood flow.
SETTING: University hospital laboratory.
SUBJECTS: A total of 21 pigs weighing 32 +/- 3 kg.
INTERVENTIONS: The anesthetized pigs were subjected to a penetrating liver injury, which resulted in a mean +/- sem loss of 40% +/- 5% of estimated whole blood volume within 30 mins and mean arterial pressures of <20 mm Hg. When heart rate declined progressively, pigs randomly received a bolus dose and continuous infusion of either vasopressin (0.4 units/kg and 0.04 units.kg-1.min-1, n = 7), or epinephrine (45 microg/kg and 5 microg.kg(-1).min(-1), n = 7), or an equal volume of saline placebo (n = 7), respectively. At 30 mins after drug administration, all surviving animals were fluid resuscitated while bleeding was surgically controlled.
MEASUREMENTS AND MAIN RESULTS: Mean +/- sem arterial blood pressure at 2.5 and 10 mins was significantly (p <.001) higher after vasopressin vs. epinephrine vs. saline placebo (82 +/- 14 vs. 23 +/- 4 vs. 11 +/- 3 mm Hg, and 42 +/- 4 vs. 10 +/- 5 vs. 6 +/- 3 mm Hg, respectively). Although portal vein blood flow was temporarily impaired by vasopressin, it was subsequently restored and significantly (p <.01) higher when compared with epinephrine or saline placebo (9 +/- 5 vs. 121 +/- 3 vs. 54 +/- 22 mL/min and 150 +/- 20 vs. 31 +/- 17 vs. 0 +/- 0 mL/min, respectively). Hepatic and renal artery blood flow was significantly higher throughout the study in the vasopressin group; however, no further bleeding was observed. Despite a second bolus dose, all epinephrine- and saline placebo-treated animals died within 15 mins after drug administration. By contrast, seven of seven vasopressin-treated animals survived until fluid replacement, and 60 mins thereafter, without further vasopressor therapy (p <.01). Moreover, blood flow to liver, gut, and kidney returned to normal values in the postshock phase.
CONCLUSIONS: Vasopressin, but not epinephrine or saline placebo, improved short-term survival in a porcine model of uncontrolled hemorrhagic shock after liver injury when surgical intervention and fluid replacement was delayed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682488     DOI: 10.1097/01.CCM.0000060014.75282.69

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  26 in total

1.  Impact of low-dose vasopressin on trauma outcome: prospective randomized study.

Authors:  Stephen M Cohn; Janet McCarthy; Ronald M Stewart; Rachelle B Jonas; Daniel L Dent; Joel E Michalek
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

Review 2.  [Treatment of hemorrhagic shock. New therapy options].

Authors:  W G Voelckel; A von Goedecke; D Fries; A C Krismer; V Wenzel; K H Lindner
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

3.  New trends in resuscitation.

Authors:  Hasan B Alam; George C Velmahos
Journal:  Curr Probl Surg       Date:  2011-08       Impact factor: 1.909

4.  Cerebral effects of resuscitation with either epinephrine or vasopressin in an animal model of hemorrhagic shock.

Authors:  Jan Küchler; Stephan Klaus; Ludger Bahlmann; Nils Onken; Alexander Keck; Emma Smith; Jan Gliemroth; Claudia Ditz
Journal:  Eur J Trauma Emerg Surg       Date:  2019-05-24       Impact factor: 3.693

5.  Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial.

Authors:  Carrie A Sims; Daniel Holena; Patrick Kim; Jose Pascual; Brian Smith; Neils Martin; Mark Seamon; Adam Shiroff; Shariq Raza; Lewis Kaplan; Elena Grill; Nicole Zimmerman; Christopher Mason; Benjamin Abella; Patrick Reilly
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

Review 6.  Resuscitation after hemorrhagic shock: the effect on the liver--a review of experimental data.

Authors:  Iosifina I Karmaniolou; Kassiani A Theodoraki; Nikolaos F Orfanos; Georgia G Kostopanagiotou; Vasileios E Smyrniotis; Anastasios I Mylonas; Nikolaos F Arkadopoulos
Journal:  J Anesth       Date:  2012-12-29       Impact factor: 2.078

7.  The evaluation of different treatment protocols for trauma-induced lung injury in rats.

Authors:  Hızır Ufuk Akdemir; Aygül Güzel; Celal Katı; Latif Duran; Hasan Alaçam; Ayhan Gacar; Tolga Güvenç; Naci Murat; Bülent Sişman
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

8.  Fluid sparing and norepinephrine use in a rat model of resuscitated haemorrhagic shock: end-organ impact.

Authors:  Sophie Dunberry-Poissant; Kim Gilbert; Caroline Bouchard; Frédérique Baril; Anne-Marie Cardinal; Sydnée L'Ecuyer; Mathieu Hylands; François Lamontagne; Guy Rousseau; Emmanuel Charbonney
Journal:  Intensive Care Med Exp       Date:  2018-11-12

9.  Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock. Three cases and a brief analysis of the literature.

Authors:  A C Krismer; V Wenzel; W G Voelckel; P Innerhofer; K H Stadlbauer; T Haas; M Pavlic; H J Sparr; K H Lindner; A Koenigsrainer
Journal:  Anaesthesist       Date:  2005-03       Impact factor: 1.041

Review 10.  [New therapeutic approaches in the treatment of shock: hypertonic hyperoncotic solutions and vasopressin].

Authors:  A Meier-Hellman; G Burgard
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.